<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18711267</article-id><article-id pub-id-type="pmc">2636132</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_5_391_42415</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium</subject></subj-group></article-categories><title-group><article-title>Impact of highly active antiretroviral therapy on ophthalmic manifestations inhuman immunodeficiency virus / acquired immune deficiency syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Venkatesh</surname><given-names>Kartik K</given-names></name><degrees>BA</degrees></contrib><contrib contrib-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><degrees>MD; N</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><degrees>MBBS, PhD</degrees></contrib></contrib-group><aff>Brown University Medical School (KKV), Providence, RI, USA; MedicalResearch Foundation (JB), Sankara Nethralaya, Chennai, India; YRGCentre for AIDS Research and Education (NK), VHS, Chennai, TamilNadu, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. N. Kumarasamy, YRG Centre for AIDS Researchand Education, Voluntary Health Services, Taramani, Chennai - 600 113,India. Email: <email>kumarasamy@yrgcare.org</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2008</year></pub-date><volume>56</volume><issue>5</issue><fpage>391</fpage><lpage>393</lpage><history><date date-type="received"><day>08</day><month>8</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2008</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work isproperly cited.</license-p></license></permissions><abstract><p>Highly active antiretroviral therapy (HAART) has changed the face of human immunodeficiency virus (HIV)acquired immune deficiency syndrome (AIDS) by leading to dramatic decreases in HIV-related morbidity andmortality in the developed as well as developing world. Since the introduction of HAART, the incidence ofocular opportunistic infections causing retinitis has dramatically decreased, and clinicians should be awareof changes in the clinical presentation of ocular manifestations of HIV. As studies of HIV disease after theintroduction of HAART continue to become available, more thorough descriptions of treated patients withocular opportunistic infections will include side-effects and toxicities of therapy. This review focuses on theimpact of HAART on the ocular manifestations of HIV.</p></abstract><kwd-group><kwd>Acquired immune deficiency syndrome</kwd><kwd>eye</kwd><kwd>highly active antiretroviral treatment</kwd><kwd>human immunodeficiency virus</kwd><kwd>India</kwd><kwd>ophthalmology</kwd><kwd>therapy</kwd></kwd-group></article-meta></front><body><p>Highly active antiretroviral therapy (HAART) has changedthe face of human immunodeficiency virus (HIV) acquiredimmunodeficiency syndrome (AIDS) by leading to dramaticdecreases in HIV-related morbidity and mortality in thedeveloped as well as developing world.<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref> In India,generic HAART has been shown to be safe, well-tolerated, and effectivein increasing CD4 counts, and suppressing plasma viral load inpatients with advanced HIV.<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref> The production ofantiretroviral drugs by generic Indian drug manufacturers throughout thedeveloping world has drastically reduced the price of HAARTto less than one USD per day, and consequently increased accessto treatment in resource-limited settings.<xref ref-type="bibr" rid="ref5">5</xref> This review focuses onthe impact of HAART on the ocular manifestations of HIV.</p><p>Since the introduction of HAART, the incidence ofocular opportunistic infections causing retinitis, such ascytomegalovirus (CMV), varicella zoster virus (VZV),tuberculosis, and toxoplasmosis, has dramatically decreased.<xref ref-type="bibr" rid="ref6">6</xref>However, immune recovery uveitis secondary to HAART hasbecome a major visually-threatening condition.<xref ref-type="bibr" rid="ref7">7</xref>-<xref ref-type="bibr" rid="ref9">9</xref> Highrates of ocular syphilis have been documented as well among patientsreceiving HAART.<xref ref-type="bibr" rid="ref10">10</xref> While HAART may have also decreasedthe incidence of other retinopathies associated with HIV, thereported incidence of these conditions was so low before theera of HAART that quantifying any changes in incidence isnot feasible.</p><p>The standard HAART regimen since the late 1990s hasconsisted of combination therapy of three antiretroviral drugsfrom the three major drug categories, namely nucleosidereverse transcriptase inhibitors (NRTIs), non-nucleoside reversetranscriptase inhibitors (NNRTIs) and protease inhibitors(PIs). The goal of HAART has been to achieve sustained viralsuppression, minimize drug resistance, and simplify dosagepattern. The immune recovery resulting from HAART is due toan absolute increase in CD4 cell count first through an increasein memory T cells followed by the renewed production of na&#x000ef;veCD4 T cells.<xref ref-type="bibr" rid="ref11">11</xref> As in the developed world, the introduction ofgeneric HAART in India has led to a dramatic reduction in theincidence of opportunistic infections.<xref ref-type="bibr" rid="ref2">2</xref></p><sec sec-type=""><title>Changes in ocular manifestations of HIV inthe pre- and post-HAART eras</title><p>There have been dramatic changes in the incidence of ocularmanifestations of HIV between the pre- and post-HAARTera. In the era prior to HAART, our center described the firsttwo cases, one patient with CMV retinitis and the other withendogenous endophthalmitis, of ocular involvement of HIVin India in 1995.<xref ref-type="bibr" rid="ref12">12</xref> Before the introduction of HAART, CMVretinitis affected 30-40% of HIV-infected individuals,<xref ref-type="bibr" rid="ref13">13</xref> withvisual loss primarily due to CMV involvement of the posteriorretina and retinal detachment;<xref ref-type="bibr" rid="ref14">14</xref> it was also suggested that uponcareful examination, 30% of patients with CD4 cell countsbelow 50 cells/&#x000b5;l would be harboring CMV retinitis.<xref ref-type="bibr" rid="ref15">15</xref> At thattime a study from our center documented CMV retinitis andcotton-wool spots caused by HIV-related microvasculopathyas the most frequently encountered ocular lesions. A lowerprevalence (45.7%) of ocular involvement was observed inHIV infection among Indian patients than other regionalsettings.<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref> Additionally, a study conducted at ourcenter in Indian children infected with HIV found a high prevalence ofocular and systemic lesions, most commonly anterior uveitisfollowed by CMV retinitis.<xref ref-type="bibr" rid="ref18">18</xref></p><p>In the HAART era, it has been suggested that there has beenan estimated 80% decrease in the incidence of CMV retinitis;<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref19">19</xref> however, there is evidence that suggests that this decrease hasnow been leveled off as patients continue to present with CMVretinitis after initiating HAART.<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref> It has alsobeen reported that the clinical picture and level of intraocular pressure aresimilar in the pre-HAART and post-HAART era.<xref ref-type="bibr" rid="ref21">21</xref> Highlyactive antiretroviral therapy induces at least partial immunerestoration and improves the long-term outcome of CMVretinitis.<xref ref-type="bibr" rid="ref6">6</xref> However, after the initiation of HAART, a relapseof CMV retinitis as vitritis has been reported.<xref ref-type="bibr" rid="ref8">8</xref> Recurrencesof CMV can be due to progressive immune dysfunction,inadequate intraocular drug levels, and drug resistance. Bystudying CMV retinitis, physicians can investigate whetherthe rejuvenated immune system resulting from HAART caneffectively control opportunistic infections caused by AIDS.</p></sec><sec sec-type=""><title>Treatment options for CMV and associatedcomplications in the era of HAART</title><p>Treatment of CMV has changed since the introduction ofHAART. Prior to HAART, patients had to remain on maintenanceanti-CMV regimens to decrease rates of recurrence. However,HAART has led to low levels of CMV recurrence, even whenanti-CMV regimens are stopped.<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref22">22</xref> It has beensuggested that patients who can sustain an elevated CD4 cell count due toHAART on two consecutive measurements three months apartand whose CMV retinitis remains regressed on anti-CMVtherapy for more than four months may discontinue anti-CMV therapy with close clinical monitoring for reactivation.<xref ref-type="bibr" rid="ref23">23</xref>The conventionally used definition of immune recoveryis a CD4 cell count &#x0003e;100 cells/&#x000b5;l, which has been used as aguideline for discontinuation of anti-CMV therapy.<xref ref-type="bibr" rid="ref24">24</xref> Despitethe marked increase in CD4+ cell counts, it may be advisableto not discontinue anti-CMV medications during the first fewmonths of initiating HAART.<xref ref-type="bibr" rid="ref25">25</xref> Due to the small number of casesreported and the variable periods of follow-up, the relapse rateof CMV retinitis among patients who discontinue anti-CMVtreatment remains unclear.</p><p>Since the advent of HAART, immune recovery uveitis (IRU)has become an ocular manifestation described in patientswith inactive CMV retinitis.<xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref26">26</xref> The reportedincidence of IRU has been shown to vary widely and limited data is availableof possible risk factors.<xref ref-type="bibr" rid="ref27">27</xref>-<xref ref-type="bibr" rid="ref29">29</xref> Some HIV-infectedindividuals experience clinical deterioration after initiating antiretroviraltherapy that is believed to be a result of the restored immunesystem to mount an exuberant inflammatory response.Immune reconstitution syndrome can cause posterior segmentinflammation in CMV retinitis and can lead to visual morbidityin patients with AIDS.<xref ref-type="bibr" rid="ref29">29</xref> We have reported a case of immunereconstitution in an HIV-infected Indian male receivingHAART with CMV retinitis who developed panuveitis withhypopyon, which was related to immune recovery mediatedby combination protease inhibitors-based antiretroviraltherapy.<xref ref-type="bibr" rid="ref30">30</xref></p></sec><sec sec-type=""><title>Conclusion: future clinical trajectories oftreating ocular manifestations of HIV</title><p>Clinicians should be aware of changes in the clinicalpresentation of ocular manifestations of HIV since theintroduction of HAART. Among patients with CMV in theHAART era, immune recovery may be associated with a greaternumber of inflammatory complications, including macular edema and epiretinal membrane formation.<xref ref-type="bibr" rid="ref21">21</xref> Given the range of ocular manifestations of HIV, routine ocular examinationsand screening for visual loss is recommended in patients withCD4 counts &#x0003c;50 cells/&#x000b5;l.<xref ref-type="bibr" rid="ref31">31</xref> As studies on HIV disease afterthe introduction of HAART continue to become available,more thorough descriptions of treated patients with ocularopportunistic infections will include side-effects and toxicitieson therapy. As increasing number of HIV-infected individualspresent with treatment failure in resource-limited settings suchas India, the risk of ophthalmic complications may increase.Further research is needed to study the effects of the restoredimmune system following HAART on the eye and to identifythe best therapeutic approach for HIV-infected patients.</p></sec></body><back><fn-group><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palella</surname><given-names>F</given-names></name><name><surname>Delaney</surname><given-names>KM</given-names></name><name><surname>Moorman</surname><given-names>AC</given-names></name><name><surname>Loveless</surname><given-names>MO</given-names></name><name><surname>Fuhrer</surname><given-names>J</given-names></name><name><surname>Satten</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Declining morbidity and mortality among patientswith advanced human immunodeficiency virus infection: HIVOutpatient Study Investigators</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>853</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9516219</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Chaguturu</surname><given-names>SK</given-names></name><name><surname>Cecelia</surname><given-names>AJ</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name><name><surname>Flanigan</surname><given-names>TP</given-names></name><etal/></person-group><article-title>The changing naturalhistory of HIV disease: Before and after the introduction ofgeneric antiretroviral therapy in southern India</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><fpage>1525</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16231268</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Chaguturu</surname><given-names>SK</given-names></name><name><surname>Mahajan</surname><given-names>AP</given-names></name><name><surname>Flanigan</surname><given-names>TP</given-names></name><name><surname>Balakrishnan</surname><given-names>P</given-names></name><etal/></person-group><article-title>The safety, tolerability andeffectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India</article-title><source>AIDS</source><year>2003</year><volume>17</volume><fpage>2265</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">14523287</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name><name><surname>Flanigan</surname><given-names>TP</given-names></name><name><surname>Balakrishnan</surname><given-names>TP</given-names></name><name><surname>Cecelia</surname><given-names>A</given-names></name><name><surname>Carpenter</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Rapid viral load suppressionfollowing generic highly active antiretroviral therapy in SouthernIndian HIV-infected patients</article-title><source>AIDS</source><year>2005</year><volume>19</volume><fpage>625</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15802982</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name></person-group><article-title>Generic antiretroviral drugs-will they be theanswer to HIV in the developing world?</article-title><source>Lancet</source><year>2004</year><volume>364</volume><fpage>3</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15234833</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitcup</surname><given-names>S</given-names></name><name><surname>Fortin</surname><given-names>E</given-names></name><name><surname>Nussenblatt</surname><given-names>RB</given-names></name><name><surname>Polis</surname><given-names>MA</given-names></name><name><surname>Muccioli</surname><given-names>C</given-names></name><name><surname>Belfort</surname><given-names>R</given-names></name></person-group><article-title>Therapeutic effect of combination antiretroviral therapyon cytomegalovirus retinitis</article-title><source>J Am Med Assoc</source><year>1997</year><volume>277</volume><fpage>1519</fpage><lpage>20</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyraz-Ikiz</surname><given-names>H</given-names></name><name><surname>Witmer</surname><given-names>JP</given-names></name><name><surname>Frissen</surname><given-names>PH</given-names></name></person-group><article-title>Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiationof highly active antiretroviral therapy</article-title><source>AIDS</source><year>1999</year><volume>13</volume><fpage>867</fpage><pub-id pub-id-type="pmid">10357392</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavellas</surname><given-names>M</given-names></name><name><surname>Plummer</surname><given-names>DJ</given-names></name><name><surname>Macdonald</surname><given-names>JC</given-names></name><name><surname>Torriani</surname><given-names>FJ</given-names></name><name><surname>Shufelt</surname><given-names>CL</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Incidence of immune recovery vitritisin cytomegalovirus retinitis patients following institution ofsuccessful highly active antiretroviral therapy</article-title><source>J Infect Dis</source><year>1999</year><volume>179</volume><fpage>697</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">9952380</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>M</given-names></name><name><surname>Zegans</surname><given-names>M</given-names></name><name><surname>Pavan</surname><given-names>PR</given-names></name><name><surname>O&#x02032;Donnell</surname><given-names>JJ</given-names></name><name><surname>Sattler</surname><given-names>F</given-names></name><name><surname>Rao</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cytomegalovirus retinitis after initiation of highly activeantiretroviral therapy</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1443</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9164318</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balba</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>PN</given-names></name><name><surname>James</surname><given-names>AN</given-names></name><name><surname>Malani</surname><given-names>A</given-names></name><name><surname>Palestine</surname><given-names>AG</given-names></name><name><surname>Welch</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Ocular syphilis in HIV-positive patients receiving highly activeantiretroviral therapy</article-title><source>J Med</source><year>2006</year><volume>119</volume><fpage>21</fpage><lpage>5</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autran</surname><given-names>B</given-names></name><name><surname>Carcelain</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>TS</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Mathez</surname><given-names>D</given-names></name><name><surname>Tubiana</surname><given-names>R</given-names></name><etal/></person-group><article-title>Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>112</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9204894</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Badrinath</surname><given-names>SS</given-names></name></person-group><article-title>Ocular lesions in AIDS:A report of first two cases in India</article-title><source>Indian J Ophthalmol</source><year>1995</year><volume>43</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8818313</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>D</given-names></name><name><surname>Saah</surname><given-names>AJ</given-names></name><name><surname>Bacellar</surname><given-names>H</given-names></name><name><surname>Phair</surname><given-names>J</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical manifestations of AIDS in the era of pneumocystisprophylaxis: Multicenter AIDS Cohort Study</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>1922</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7902536</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holbrook</surname><given-names>J</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Weinberg</surname><given-names>DV</given-names></name><name><surname>Lewis</surname><given-names>RA</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Friedberg</surname><given-names>D</given-names></name><etal/></person-group><article-title>Visual loss in patients with cytomegalovirusretinitis and acquired immunodeficiency syndrome beforewidespread availability of highly active antiretroviral therapy</article-title><source>Arch Ophthomol</source><year>2003</year><volume>121</volume><fpage>99</fpage><lpage>107</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuppermann</surname><given-names>B</given-names></name><name><surname>Petty</surname><given-names>JG</given-names></name><name><surname>Richman</surname><given-names>DD</given-names></name><name><surname>Mathews</surname><given-names>WC</given-names></name><name><surname>Fullerton</surname><given-names>SC</given-names></name><name><surname>Rickman</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Correlation between CD4+ counts and prevalenceof cytomegalovirus retinitis and human immunodeficiencyvirus-related noninfectious retinal vasculopathy in patientswith acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>115</volume><fpage>575</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8098183</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>A</given-names></name><name><surname>Raizada</surname><given-names>S</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Ophthalmic manifestations of human immunodeficiency virus(HIV) infection in India</article-title><source>Indian J Ophthalmol</source><year>1999</year><volume>47</volume><fpage>87</fpage><lpage>93</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>George</surname><given-names>AN</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Ocular lesions associated with HIUV infection in India: A seriesof 100 consecutive patients evaluated at a referral center</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10653406</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>AA</given-names></name><name><surname>George</surname><given-names>AE</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Mothi</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Ocular and systemic lesions in children with HIV</article-title><source>Indian J Pediatr</source><year>2000</year><volume>67</volume><fpage>721</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11105421</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>M</given-names></name><name><surname>Stanley</surname><given-names>H</given-names></name><name><surname>Holtzer</surname><given-names>C</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names></name></person-group><article-title>Natural history and outcome of new AIDS-related cytomegalovirusretinitis diagnosed in the era of highly active antiretroviral therapy</article-title><source>Clin Infect Dis</source><year>2000</year><volume>30</volume><fpage>231</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10619774</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>D</given-names></name><name><surname>Van Natta</surname><given-names>ML</given-names></name><name><surname>Holbrook</surname><given-names>JT</given-names></name><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Meinert</surname><given-names>CL</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Longitudinal study of the ocular complicationsof AIDS: 1, Ocular diagnoses at enrollment</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>780</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17258320</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>D</given-names></name><name><surname>Van Natta</surname><given-names>ML</given-names></name><name><surname>Holbrook</surname><given-names>JT</given-names></name><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Meinert</surname><given-names>CL</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Longitudinal study of the ocular complications ofAIDS: 2, Ocular examination results at enrollment</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>787</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17210182</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>D</given-names></name><name><surname>Bolton</surname><given-names>SG</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Palestine</surname><given-names>AG</given-names></name></person-group><article-title>Discontinuinganticytomegalovirus therapy in patients with immune reconstitutionafter combination antiretroviral therapy</article-title><source>Am J Ophthalmol</source><year>1998</year><volume>126</volume><fpage>817</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">9860006</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>J</given-names></name><name><surname>Karavellas</surname><given-names>MP</given-names></name><name><surname>Torriani</surname><given-names>FJ</given-names></name><name><surname>Morse</surname><given-names>LS</given-names></name><name><surname>Smith</surname><given-names>IL</given-names></name><name><surname>Reed</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Highly active antiretroviral therapy-relatedimmune recovery in AIDS patients with cytomegalovirus retinitis</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><fpage>877</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10811078</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><article-title>Guidelines for preventing opportunistic infections among HIVinfected persons-2002. Recommendations of the US Public HealthService and the Infectious Diseases Society of America</article-title><source>MMWR Recomm Rep</source><year>2002</year><volume>51</volume><fpage>1</fpage><lpage>52</lpage></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Fogla</surname><given-names>R</given-names></name><name><surname>Gopal</surname><given-names>L</given-names></name><name><surname>Narayana</surname><given-names>KM</given-names></name><name><surname>Banker</surname><given-names>AS</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><etal/></person-group><article-title>Current approaches to diagnosis and management of ocularlesions in human immunodeficiency virus positive patients</article-title><source>Indian J Ophthalmol</source><year>2002</year><volume>50</volume><fpage>83</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12194584</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Karavellas</surname><given-names>MP</given-names></name><name><surname>MacDonald</surname><given-names>JC</given-names></name><name><surname>Plummer</surname><given-names>DJ</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name></person-group><article-title>Characterization of reactivation of cytomegalovirus retinitis inpatients healed after treatment with highly active antiretroviraltherapy</article-title><source>Retina</source><year>2000</year><volume>20</volume><fpage>151</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10783947</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavellas</surname><given-names>M</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name><name><surname>MacDonald</surname><given-names>JC</given-names></name><name><surname>Shufelt</surname><given-names>CL</given-names></name><name><surname>Lowder</surname><given-names>CY</given-names></name><name><surname>Plummer</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Immune recovery vitritis and uveitis in AIDS:Clinical predictors, sequelae and treatment outcomes</article-title><source>Retina</source><year>2001</year><volume>21</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11217922</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>J</given-names></name><name><surname>Min</surname><given-names>YI</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Friedberg</surname><given-names>DN</given-names></name><name><surname>Dieterich</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Risk of immune recovery uveitis in patientswith AIDS and cytomegalovirus retinitis</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>113</volume><fpage>684</fpage><lpage>94</lpage></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>Q</given-names></name><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Bolton</surname><given-names>SG</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name></person-group><article-title>Immunerecovery uveitis in patients with AIDS and cytomegalovirusretinitis after highly active antiretroviral therapy</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>634</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10844056</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Choudhry</surname><given-names>S</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Immunerecovery vitritis presenting as panuveitis following therapy withprotease inhibitors</article-title><source>Indian J Ophthalmol</source><year>2000</year><volume>48</volume><fpage>313</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11340892</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name><name><surname>Flanigan</surname><given-names>TP</given-names></name><name><surname>Mayer</surname><given-names>KH</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Clinical profile of HIV in India</article-title><source>Indian J Med Res</source><year>2005</year><volume>121</volume><fpage>377</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15817951</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name><name><surname>Cecelia</surname><given-names>AJ</given-names></name><name><surname>Yepthomi</surname><given-names>T</given-names></name><name><surname>Balakrishnan</surname><given-names>P</given-names></name><name><surname>Saghayam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Reasons for modification ofgeneric highly active antiretroviral therapeutic regimens amongpatients in southern India</article-title><source>J Acquir Immune Deficiency Syndrome</source><year>2006</year><volume>41</volume><fpage>53</fpage><lpage>8</lpage></element-citation></ref></ref-list></back></article>